- Home
- CLGN vs ATRA Comparison
CLGN vs ATRA Comparison
Compare CLGN & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLGN
- ATRA
- Stock Information
- Founded
- CLGN 2004
- ATRA 2012
- Country
- CLGN Israel
- ATRA United States
- Employees
- CLGN N/A
- ATRA N/A
- Industry
- CLGN Industrial Specialties
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLGN Health Care
- ATRA Health Care
- Exchange
- CLGN Nasdaq
- ATRA Nasdaq
- Market Cap
- CLGN 46.2M
- ATRA 48.5M
- IPO Year
- CLGN N/A
- ATRA 2014
- Fundamental
- Price
- CLGN $3.47
- ATRA $7.11
- Analyst Decision
- CLGN Strong Buy
- ATRA Buy
- Analyst Count
- CLGN 2
- ATRA 6
- Target Price
- CLGN $12.50
- ATRA $25.70
- AVG Volume (30 Days)
- CLGN 5.1K
- ATRA 178.5K
- Earning Date
- CLGN 04-03-2025
- ATRA 03-27-2025
- Dividend Yield
- CLGN N/A
- ATRA N/A
- EPS Growth
- CLGN N/A
- ATRA N/A
- EPS
- CLGN N/A
- ATRA N/A
- Revenue
- CLGN $650,000.00
- ATRA $100,439,000.00
- Revenue This Year
- CLGN N/A
- ATRA $1,281.31
- Revenue Next Year
- CLGN $692.59
- ATRA N/A
- P/E Ratio
- CLGN N/A
- ATRA N/A
- Revenue Growth
- CLGN N/A
- ATRA 2111.34
- 52 Week Low
- CLGN $3.24
- ATRA $5.40
- 52 Week High
- CLGN $6.75
- ATRA $23.45
- Technical
- Relative Strength Index (RSI)
- CLGN 36.66
- ATRA 37.35
- Support Level
- CLGN $3.52
- ATRA $8.05
- Resistance Level
- CLGN $3.70
- ATRA $9.05
- Average True Range (ATR)
- CLGN 0.16
- ATRA 0.85
- MACD
- CLGN -0.02
- ATRA -0.06
- Stochastic Oscillator
- CLGN 3.64
- ATRA 2.23
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).